[go: up one dir, main page]

MX2007007720A - Derivados de pirrolidinio como receptores m3 muscarinicos. - Google Patents

Derivados de pirrolidinio como receptores m3 muscarinicos.

Info

Publication number
MX2007007720A
MX2007007720A MX2007007720A MX2007007720A MX2007007720A MX 2007007720 A MX2007007720 A MX 2007007720A MX 2007007720 A MX2007007720 A MX 2007007720A MX 2007007720 A MX2007007720 A MX 2007007720A MX 2007007720 A MX2007007720 A MX 2007007720A
Authority
MX
Mexico
Prior art keywords
pyrrolinidium
derivatives
muscarinic receptors
compounds
muscarinic
Prior art date
Application number
MX2007007720A
Other languages
English (en)
Inventor
Neil John Press
Stephen Paul Collingwood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007007720A publication Critical patent/MX2007007720A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos de la formula (I) (ver formula (I)), en forma de sal o en forma de ion hibrido, en la que R1, R2, R3, R4 y R5 tienen los significados indicados en la descripcion, son utiles para tratar condiciones que son mediadas por el receptor muscarinico M3. Tambien se describen composiciones farmaceuticas que contienen los compuestos, y un proceso para preparar los compuestos.
MX2007007720A 2004-12-24 2005-12-22 Derivados de pirrolidinio como receptores m3 muscarinicos. MX2007007720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428416.2A GB0428416D0 (en) 2004-12-24 2004-12-24 Organic compounds
PCT/EP2005/013896 WO2006066928A1 (en) 2004-12-24 2005-12-22 Pyrrolinidium derivatives as m3 muscarinic receptors

Publications (1)

Publication Number Publication Date
MX2007007720A true MX2007007720A (es) 2007-08-14

Family

ID=34130966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007720A MX2007007720A (es) 2004-12-24 2005-12-22 Derivados de pirrolidinio como receptores m3 muscarinicos.

Country Status (16)

Country Link
US (1) US8383625B2 (es)
EP (1) EP1831202B1 (es)
JP (1) JP2008525358A (es)
KR (1) KR101256242B1 (es)
CN (1) CN101087777B (es)
AT (1) ATE541839T1 (es)
AU (1) AU2005318423B2 (es)
BR (1) BRPI0519208A2 (es)
CA (1) CA2589744C (es)
ES (1) ES2377486T3 (es)
GB (1) GB0428416D0 (es)
MX (1) MX2007007720A (es)
PL (1) PL1831202T3 (es)
PT (1) PT1831202E (es)
RU (1) RU2412183C2 (es)
WO (1) WO2006066928A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2627982C (en) 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
US7399861B2 (en) 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
KR101495708B1 (ko) 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물
PT2197841E (pt) 2007-09-07 2012-01-02 Theravance Inc Compostos contendo guanidina úteis como antagonistas do receptor muscarínico
JP2011506477A (ja) 2007-12-14 2011-03-03 セラヴァンス， インコーポレーテッド ムスカリン受容体拮抗薬として有用なアミジン含有化合物
JP4837800B2 (ja) 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
CN104968656B (zh) 2012-12-19 2017-08-11 诺华股份有限公司 自分泌运动因子抑制剂
JP6223543B2 (ja) 2013-03-15 2017-11-01 ボドール ラボラトリーズ， インコーポレイテッド 多汗症の処置のための抗コリン作用性グリコピロレートエステル
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
EP3134398A1 (en) 2014-04-24 2017-03-01 Novartis Ag Autotaxin inhibitors
US20180228770A1 (en) 2015-07-21 2018-08-16 Bodor Laboratories, Inc. Formulation for soft anticholinergic analogs
TWI719046B (zh) 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59709927D1 (de) 1996-11-11 2003-05-28 Noe Christian Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR044851A1 (es) 2003-06-24 2005-10-05 Novartis Ag Compuestos heterociclicos, antagonistas del receptor m3 muscarinico
GB0428418D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
EP2227234B1 (en) * 2007-10-15 2014-05-07 Can-Fite Biopharma Ltd. Method for inducing hepatocyte proliferation and uses thereof

Also Published As

Publication number Publication date
CN101087777A (zh) 2007-12-12
KR101256242B1 (ko) 2013-04-17
EP1831202A1 (en) 2007-09-12
EP1831202B1 (en) 2012-01-18
US20090291960A1 (en) 2009-11-26
AU2005318423B2 (en) 2009-12-03
ATE541839T1 (de) 2012-02-15
US8383625B2 (en) 2013-02-26
BRPI0519208A2 (pt) 2008-12-30
JP2008525358A (ja) 2008-07-17
GB0428416D0 (en) 2005-02-02
RU2412183C2 (ru) 2011-02-20
RU2007128080A (ru) 2009-01-27
WO2006066928A1 (en) 2006-06-29
KR20070088730A (ko) 2007-08-29
PT1831202E (pt) 2012-04-11
AU2005318423A1 (en) 2006-06-29
CA2589744A1 (en) 2006-06-29
CN101087777B (zh) 2010-12-08
CA2589744C (en) 2012-08-28
PL1831202T3 (pl) 2012-06-29
ES2377486T3 (es) 2012-03-28

Similar Documents

Publication Publication Date Title
MXPA05011739A (es) Derivados de quinuclidina que se enlazan con los receptores muscarinicos m3.
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
TW200519106A (en) Organic compounds
MX2009004715A (es) Compuestos heterociclicos como agentes antiinflamatorios.
TW200517386A (en) Organic compounds
TN2010000167A1 (en) Organic compounds
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
GB0305152D0 (en) Organic compounds
MXPA05013823A (es) Derivados de pirrolidinio y piperidino como ligandos para el receptor m3 muscarinico.
TW200617009A (en) Organic compounds
ZA201000079B (en) Organic compounds
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
GB0428418D0 (en) Organic compounds
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
MX2007006374A (es) Derivados del 5-hidroxi-benzotiazol que tienen actividad agonista del adrenoreceptor-beta-2.
UA98772C2 (ru) Производные циклопропиламина как модуляторы н3-гистаминового рецептора
MX2007007720A (es) Derivados de pirrolidinio como receptores m3 muscarinicos.
MY150990A (en) Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
TW200722418A (en) Novel compounds
TNSN05279A1 (en) Quinuclidine derivatives binding to mucarinic m3 receptors
TNSN06410A1 (en) Pyrrolopyridine derivatives and their use as crth2 antagonists
WO2005075420A3 (en) Pyrrolidine derivatives acting as ccr3-receptor antagonists
UA94242C2 (ru) Производные бензотиазолциклобутиламина и их применение как лигандов рецепторов гистамина-3
TNSN08536A1 (en) Quinolinone derivatives and their pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration